Ultrasound company SonoSite Inc. (NSDQ:SONO) added two new med-tech veterans to its executive team this week.
On Tuesday the Bothell, Wash.-based company announced the appointment of Brian Noyes to VP of marketing for North and South America.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Ultrasound company SonoSite Inc. (NSDQ:SONO) added two new med-tech veterans to its executive team this week.
On Tuesday the Bothell, Wash.-based company announced the appointment of Brian Noyes to VP of marketing for North and South America.
Tengion Inc. (NSDQ:TNGN) chief scientific officer Timothy Bertram will handle CEO duties while the company searches for a new top executive following the June 30 resignation of Dr. Steven Nichtberger.
The gold standard in long-term glucose monitoring for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.
Although the American Diabetes Association has deemed the HbA1c test an effective tool for diagnosing diabetes, kidney doctors recently determined that the HbA1c is not as useful for managing patients with diabetes and advanced kidney failure.
InspireMD Inc. (OTC:NSPR) launched its MGuard coronary stent system in India.
The Tel Aviv-based firm’s flagship product is the first mesh-based coronary stent system available in the country, the company said.
The CE Mark approved MGuard stent is wrapped with a polymer mesh sleeve designed to protect acute MI patients against embolism. Kirloskar Technologies P. Ltd., which has already closed an initial order for the stent in India, will be InspireMD’s distributor of the product, according to the company.
A group of Cincinnati gastroenterologists have been joined by several business and technology partners to launch a health IT company that develops intraoperative voice-command software to document surgical procedures.
The company, eMerge Health Solutions, received $650,000 in investment commitments, including $250,000 from state-supported venture development group CincyTech.
The annual Transcatheter Cardiovascular Therapeutics conference ended Sept. 25, with a few more companies touting clinical trial results and Boston Scientific Corp. (NYSE:BSX), which took another beating from competitors this year, trying one last time to regain ground for its Taxus drug-eluting stent.